AllSci News
Royalty Pharma bets USD 425m on AstraZeneca's amyloid-clearing antibody cliramitug
New York-based Royalty Pharma plc (Nasdaq: RPRX) has agreed to buy a slice of Neurimmune's royalty interest in cliramitug, AstraZeneca's Phase III antibody...
Monopar advances first novel Wilson disease therapy in decades toward FDA approval
Monopar Therapeutics Inc. (Nasdaq: MNPR), the Wilmette, Illinois-based biopharmaceutical company, has initiated a rolling submission of a New Drug...
SKNV licenses Washington University immunotherapy patent for actinic keratosis
SKNV, a Fort Lauderdale, Florida-based compounding pharmacy and dermatology-focused drugmaker, has secured exclusive commercialization rights under a...
Western survival data converge with overall HARMONi results for ivonescimab
Miami-based Summit Therapeutics Inc. (Nasdaq: SMMT) reported updated overall survival data from its global Phase III HARMONi trial showing that the hazard...
Arrowhead challenges Ionis in severe hypertriglyceridemia with positive Phase III plozasiran data
Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) reported topline results from two pivotal Phase III trials of plozasiran in severe hypertriglyceridemia, data...
Dyne raises USD 375m ahead of first neuromuscular disease commercial launch
Waltham, Massachusetts-based Dyne Therapeutics, Inc. (Nasdaq: DYN) announced the pricing of an upsized public offering of common stock, raising...
NanoViricides seeks to test oral antiviral against Bundibugyo Ebola in DRC
Shelton, Connecticut-based NanoViricides, Inc. (NYSE American: NNVC) has applied to the Democratic Republic of Congo's regulatory agency, ACOREP, for...
Mentari adds USD 200m PIPE funding for PACAP-targeted migraine candidate
Waltham, Massachusetts-based Mentari Therapeutics, Inc. announced a $200 million private placement of common stock and pre-funded warrants, the second...
Jupiter Neuro expands into MDMA-derived psychiatry with USD 100m PharmAla deal
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual, exclusive US rights...
Tikva Allocell secures USD 8m to advance off-the-shelf CAR-T therapy for solid tumors
Singapore-based Tikva Allocell, a biotechnology company developing engineered, off-the-shelf allogeneic T-cell therapies for solid tumors, has closed an USD...
Crystalys raises USD 130m in Series B to advance dotinurad into Phase III gout trials
San Diego-based Crystalys Therapeutics, a clinical-stage biopharmaceutical company developing therapies for gout, has closed an oversubscribed USD 130...
Evogene pairs AI chemistry with ELEO to pursue oral PCSK9 inhibitors
Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN) and ELEO Inc., a private South Korean biotech based in Daejeon, announced a collaboration to discover oral...
Radiopharm repurposes PD-L1 as a radiotherapy target after immunotherapy failure
Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX), headquartered in Sydney, Australia and Malvern, Pennsylvania, reported updated data from the ongoing...
Michigan secures NIH funding to advance ASO therapy for CLN3 Batten disease
The University of Michigan at Ann Arbor has received a USD 1.35 million NIH U01 grant to conduct IND-enabling studies for an antisense oligonucleotide (ASO)...
Agios narrows PK activator pipeline, dropping tebapivat in favor of mitapivat
Agios Pharmaceuticals (Cambridge, Massachusetts) (Nasdaq: AGIO) reported topline results from a Phase II trial of tebapivat, an oral pyruvate kinase...
The AllSci Brief
Systematic R&D and deal news. Daily.